A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002

Status:
Completed

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

This is a Phase 1 study to investigate the safety and tolerability of AK002 in patients with indolent systemic mastocytosis (ISM).

Phase 1

Allakos, Inc.